Sylvain Carras

1.1k total citations
23 papers, 108 citations indexed

About

Sylvain Carras is a scholar working on Pathology and Forensic Medicine, Oncology and Immunology. According to data from OpenAlex, Sylvain Carras has authored 23 papers receiving a total of 108 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Pathology and Forensic Medicine, 9 papers in Oncology and 6 papers in Immunology. Recurrent topics in Sylvain Carras's work include Lymphoma Diagnosis and Treatment (14 papers), Chronic Lymphocytic Leukemia Research (5 papers) and Viral-associated cancers and disorders (4 papers). Sylvain Carras is often cited by papers focused on Lymphoma Diagnosis and Treatment (14 papers), Chronic Lymphocytic Leukemia Research (5 papers) and Viral-associated cancers and disorders (4 papers). Sylvain Carras collaborates with scholars based in France, Belgium and United States. Sylvain Carras's co-authors include Françoise Berger, Jean‐François Cordier, Gilles Salles, Nicolas Girard, Frédéric Garban, J Cahn, Martin Carré, Anne Thiebaut‐Bertrand, Rémy Gressin and Raphaël Itzykson and has published in prestigious journals such as SHILAP Revista de lepidopterología, Blood and Annals of Oncology.

In The Last Decade

Sylvain Carras

13 papers receiving 105 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Sylvain Carras France	6	60	41	30	24	18	23	108
Ana Karen Nunez Cortes Mexico	7	42 0.7×	13 0.3×	44 1.5×	41 1.7×	6 0.3×	12	121
Cecilie Heegaard Brahe Denmark	6	34 0.6×	10 0.2×	6 0.2×	56 2.3×	8 0.4×	13	162
J.L. Patier de la Peña Spain	7	15 0.3×	17 0.4×	35 1.2×	14 0.6×	13 0.7×	29	125
Adolfo de la Fuente Spain	6	44 0.7×	7 0.2×	19 0.6×	18 0.8×	37 2.1×	20	102
Marion Escudier France	3	24 0.4×	78 1.9×	69 2.3×	9 0.4×	3 0.2×	3	135
Razeen Mahroof United Kingdom	3	16 0.3×	13 0.3×	9 0.3×	17 0.7×	6 0.3×	5	64
Adam J. Wood United States	7	21 0.3×	6 0.1×	14 0.5×	5 0.2×	8 0.4×	15	83
Peter V. Pickens United States	6	21 0.3×	13 0.3×	11 0.4×	76 3.2×	3 0.2×	13	148
Michaela Čepelová Czechia	5	64 1.1×	5 0.1×	22 0.7×	5 0.2×	29 1.6×	18	104
Philip Monteleone United States	5	25 0.4×	17 0.4×	37 1.2×	9 0.4×	33 1.8×	7	117

Countries citing papers authored by Sylvain Carras

Since Specialization

Citations

This map shows the geographic impact of Sylvain Carras's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sylvain Carras with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sylvain Carras more than expected).

Fields of papers citing papers by Sylvain Carras

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sylvain Carras. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sylvain Carras. The network helps show where Sylvain Carras may publish in the future.

Co-authorship network of co-authors of Sylvain Carras

This figure shows the co-authorship network connecting the top 25 collaborators of Sylvain Carras. A scholar is included among the top collaborators of Sylvain Carras based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sylvain Carras. Sylvain Carras is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Bachy, Emmanuel, François‐Xavier Gros, Roberta Di Blasi, et al.. (2025). Outcome of high-grade B-cell lymphoma compared with other large B-cell lymphoma after CAR-T rescue: a DESCAR-T LYSA study. Blood Advances. 9(10). 2500–2510.

Dû, Katell Le, Adrien Chauchet, Olivier Fitoussi, et al.. (2025). Comparison of Electronic Surveillance With Routine Monitoring for Patients With Lymphoma at High Risk of Relapse: Prospective Randomized Controlled Phase 3 Trial (Sentinel Lymphoma). JMIR Cancer. 11. e65960–e65960.

Cherblanc, Fanny, Fontanet Bijou, Pierre Sesques, et al.. (2025). Synthetic control arm from mixed clinical trials and real-world data from the LYSA group for untreated diffuse large B-cell lymphoma patients aged over 80 years: a bona fide strategy for innovative clinical trials. Blood Cancer Journal. 15(1). 190–190.

Obéric, Lucie, Krimo Bouabdallah, Sylvain Carras, & Catherine Thiéblemont. (2025). Les lymphomes de la zone marginale : les différentes entités, leur diagnostic et prise en charge en 2024. Bulletin du Cancer. 112(5). 527–541.

Bonnefoix, Thierry, Sylvain Carras, Rémy Gressin, et al.. (2024). BET inhibition revealed varying MYC dependency mechanisms independent of gene alterations in aggressive B-cell lymphomas. Clinical Epigenetics. 16(1). 185–185.

Bisig, Bettina, Karine Lefort, Sylvain Carras, & Laurence de Leval. (2024). Clinical use of circulating tumor DNA analysis in patients with lymphoma. Human Pathology. 156. 105679–105679.

Boulland, Marie‐Laure, Damien Luque Paz, Sébastien Lachot, et al.. (2024). Tailored Digital PCR Follow-Up of Rare Fusion Transcripts after Initial Detection through RNA Sequencing in Hematological Malignancies. Journal of Molecular Diagnostics. 26(11). 1007–1017. 1 indexed citations

Carras, Sylvain, Barbara Burroni, Elsa Maître, et al.. (2024). Atypical meningeal localization of classical hairy cell leukemia with an impressive response to rituximab and cladribine association. A case report and literature review. SHILAP Revista de lepidopterología. 5(1). 242–246. 2 indexed citations

Cheminant, Morgane, Sylvain Carras, Julie Bruneau, et al.. (2023). KILT: A RANDOMIZED NON‐COMPARATIVE PHASE II LYSA STUDY OF LACUTAMAB WITH GEMOX VERSUS GEMOX IN RELAPSED/REFRACTORY PERIPHERAL T‐CELL LYMPHOMA. Hematological Oncology. 41(S2). 838–839.

10.

Tamburini, Jérôme, Sarah Mouche, Clément Larrue, et al.. (2023). Very short insertions in the FLT3 gene are of therapeutic significance in acute myeloid leukemia. Blood Advances. 7(24). 7576–7580. 3 indexed citations

11.

Thiéblemont, Catherine, Annarita Conconi, Christian Buske, et al.. (2023). Marsun, a Phase III, Multicenter, Open Label, Randomized, Controlled Study Investigating Mosunetuzumab-Lenalidomide Versus Investigator Choices in Patients with Relapsed or Refractory Marginal Zone Lymphoma (R/R MZL). Blood. 142(Supplement 1). 3055–3055. 5 indexed citations

12.

Bellier, Alexandre, et al.. (2022). Effectiveness of a multifaceted intervention to improve interpersonal skills of physicians in medical consultations (EPECREM): protocol for a randomised controlled trial. BMJ Open. 12(2). e051600–e051600. 1 indexed citations

13.

Tessoulin, Benoît, Catherine Thiéblemont, Kamal Bouabdallah, et al.. (2022). Humoral immune depression following autologous stem cell transplantation is a marker of prolonged response duration in patients with mantle cell lymphoma. Haematologica. 107(9). 2163–2172. 2 indexed citations

14.

Sartelet, Hervé, Cyril Fournier, Edwige Col, et al.. (2021). Extranucleolar CYCLON Staining Pattern Is Strongly Associated to Relapse/Refractory Disease in R-CHOP–treated DLBCL. HemaSphere. 5(7). e598–e598.

15.

Cristante, Justine, Bruno Tesson, Frédérique Orsini‐Piocelle, et al.. (2021). Adverse outcome in follicular lymphoma is associated with MYC rearrangements but not MYC extra copies. British Journal of Haematology. 194(2). 382–392. 7 indexed citations

16.

Cheminant, Morgane, Julie Bruneau, Sylvain Carras, et al.. (2019). KIR3DL2 IS EXPRESSED IN PERIPHERAL T‐CELL LYMPHOMAS AND MAY BE A THERAPEUTIC TARGET. Hematological Oncology. 37(S2). 204–205.

17.

Carras, Sylvain, Delphine Sénécal, Jean-Philippe Jaı̈s, et al.. (2018). Interim PET Response-adapted Strategy in Untreated Advanced Stage Hodgkin Lymphoma: Results of GOELAMS LH 2007 Phase 2 Multicentric Trial. Clinical Lymphoma Myeloma & Leukemia. 18(3). 191–198. 7 indexed citations

18.

Bulabois, Claude‐Eric, Anne Thiebaut‐Bertrand, Raphaël Itzykson, et al.. (2014). Alemtuzumab for Severe Steroid-Refractory Gastrointestinal Acute Graft-versus-Host Disease. Biology of Blood and Marrow Transplantation. 20(9). 1451–1454. 13 indexed citations

19.

Chevallier, Patrice, Nelly Robillard, Aude Charbonnier, et al.. (2012). Trastuzumab for treatment of refractory/relapsed HER2-positive adult B-ALL: results of a phase 2 GRAALL study. Blood. 119(11). 2474–2477. 11 indexed citations

20.

Garban, Frédéric, Sylvain Carras, Marie‐Christine Jacob, et al.. (2012). Extracorporeal photopheresis as a curative treatment strategy in non epidermotropic T-cell lymphoma and large granular lymphocyte leukemia. Annals of Oncology. 23(9). 2386–2390. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact